Journal of Clinical and Translational Hepatology最新文献

筛选
英文 中文
Corrigendum: Osteopontin Promotes Macrophage M1 Polarization by Activation of the JAK1/STAT1/HMGB1 Signaling Pathway in Nonalcoholic Fatty Liver Disease. 更正:骨蛋白通过激活非酒精性脂肪肝中的 JAK1/STAT1/HMGB1 信号通路促进巨噬细胞 M1 极化。
IF 3.6 3区 医学
Journal of Clinical and Translational Hepatology Pub Date : 2024-01-28 Epub Date: 2023-11-13 DOI: 10.14218/JCTH.2021.00474C
{"title":"Corrigendum: Osteopontin Promotes Macrophage M1 Polarization by Activation of the JAK1/STAT1/HMGB1 Signaling Pathway in Nonalcoholic Fatty Liver Disease.","authors":"","doi":"10.14218/JCTH.2021.00474C","DOIUrl":"https://doi.org/10.14218/JCTH.2021.00474C","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.14218/JCTH.2021.00474.].</p>","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"12 1","pages":"119-121"},"PeriodicalIF":3.6,"publicationDate":"2024-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10794274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139512483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unique Genetic Features of Lean NAFLD: A Review of Mechanisms and Clinical Implications. 瘦型非酒精性脂肪肝的独特遗传特征:机制与临床意义综述。
IF 3.6 3区 医学
Journal of Clinical and Translational Hepatology Pub Date : 2024-01-28 Epub Date: 2023-08-25 DOI: 10.14218/JCTH.2023.00252
Jasmine Tidwell, George Y Wu
{"title":"Unique Genetic Features of Lean NAFLD: A Review of Mechanisms and Clinical Implications.","authors":"Jasmine Tidwell, George Y Wu","doi":"10.14218/JCTH.2023.00252","DOIUrl":"10.14218/JCTH.2023.00252","url":null,"abstract":"<p><p>Non-alcoholic fatty liver disease (NAFLD) affects 25% of the global population. About 20% have a normal body mass index (BMI) and a variant known as lean NAFLD. Unlike typical NAFLD cases associated with obesity and diabetes, lean NAFLD causes liver disease by mechanisms not related to excess weight or insulin resistance. Genetic disorders are among the major factors in developing lean NAFLD, and genome-wide association studies have identified several genes associated with the condition. This review aims to increase awareness by describing the genetic markers linked to NAFLD and the defects involved in developing lean NAFLD.</p>","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"12 1","pages":"70-78"},"PeriodicalIF":3.6,"publicationDate":"2024-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10794266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139512486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improving the Conversion Success Rate of Hepatocellular Carcinoma: Focus on the Use of Combination Therapy with a High Objective Response Rate 提高肝细胞癌的转阴成功率:关注客观反应率高的联合疗法的应用
IF 3.6 3区 医学
Journal of Clinical and Translational Hepatology Pub Date : 2024-01-10 DOI: 10.14218/jcth.2023.00403
Qi-Feng Chen, Song Chen, Minshan Chen, N. Lyu, Ming Zhao
{"title":"Improving the Conversion Success Rate of Hepatocellular Carcinoma: Focus on the Use of Combination Therapy with a High Objective Response Rate","authors":"Qi-Feng Chen, Song Chen, Minshan Chen, N. Lyu, Ming Zhao","doi":"10.14218/jcth.2023.00403","DOIUrl":"https://doi.org/10.14218/jcth.2023.00403","url":null,"abstract":"","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"7 6","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139439477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune Regulatory Networks and Therapy of γδ T Cells in Liver Cancer: Recent Trends and Advancements 肝癌中的γδT 细胞免疫调节网络与治疗:最新趋势和进展
IF 3.6 3区 医学
Journal of Clinical and Translational Hepatology Pub Date : 2024-01-08 DOI: 10.14218/jcth.2023.00355
Kunli Yin, Kai-Jian Chu, Ming Li, Yu-Xin Duan, Yanxi Yu, Meiqing Kang, Da Fu, Rui Liao
{"title":"Immune Regulatory Networks and Therapy of γδ T Cells in Liver Cancer: Recent Trends and Advancements","authors":"Kunli Yin, Kai-Jian Chu, Ming Li, Yu-Xin Duan, Yanxi Yu, Meiqing Kang, Da Fu, Rui Liao","doi":"10.14218/jcth.2023.00355","DOIUrl":"https://doi.org/10.14218/jcth.2023.00355","url":null,"abstract":"","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"5 3","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139446758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatocellular Carcinoma Incidence and Mortality in the USA by Sex, Age, and Race: A Nationwide Analysis of Two Decades 美国按性别、年龄和种族分列的肝细胞癌发病率和死亡率:二十年来的全国性分析
IF 3.6 3区 医学
Journal of Clinical and Translational Hepatology Pub Date : 2024-01-02 DOI: 10.14218/jcth.2023.00356
Yazan Abboud, Mohamed Ismail, Hamza Khan, Esli Medina-Morales, S. Alsakarneh, F. Jaber, Nikolaos T. Pyrsopoulos
{"title":"Hepatocellular Carcinoma Incidence and Mortality in the USA by Sex, Age, and Race: A Nationwide Analysis of Two Decades","authors":"Yazan Abboud, Mohamed Ismail, Hamza Khan, Esli Medina-Morales, S. Alsakarneh, F. Jaber, Nikolaos T. Pyrsopoulos","doi":"10.14218/jcth.2023.00356","DOIUrl":"https://doi.org/10.14218/jcth.2023.00356","url":null,"abstract":"","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"121 22","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139390679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2023 Reviewer Acknowledgement. 2023 审稿人致谢。
IF 3.6 3区 医学
Journal of Clinical and Translational Hepatology Pub Date : 2023-12-28 DOI: 10.14218/JCTH.2023.000RA
Editorial Office Of Journal Of Clinical And Translational Hepatology
{"title":"2023 Reviewer Acknowledgement.","authors":"Editorial Office Of Journal Of Clinical And Translational Hepatology","doi":"10.14218/JCTH.2023.000RA","DOIUrl":"https://doi.org/10.14218/JCTH.2023.000RA","url":null,"abstract":"","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"11 7","pages":"1580-1583"},"PeriodicalIF":3.6,"publicationDate":"2023-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10752804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139074254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antiviral Therapy Favors a Lower Risk of Liver Cirrhosis in HBeAg-negative Chronic Hepatitis B with Normal Alanine Transaminase and HBV DNA Positivity. 抗病毒治疗有利于降低丙氨酸转氨酶和 HBV DNA 阳性的 HBeAg 阴性慢性乙型肝炎患者罹患肝硬化的风险。
IF 3.6 3区 医学
Journal of Clinical and Translational Hepatology Pub Date : 2023-12-28 Epub Date: 2023-08-25 DOI: 10.14218/JCTH.2023.00272
Jing Zhou, Fa-Da Wang, Lan-Qing Li, Yu-Jin Li, Shi-Yan Wang, En-Qiang Chen
{"title":"Antiviral Therapy Favors a Lower Risk of Liver Cirrhosis in HBeAg-negative Chronic Hepatitis B with Normal Alanine Transaminase and HBV DNA Positivity.","authors":"Jing Zhou, Fa-Da Wang, Lan-Qing Li, Yu-Jin Li, Shi-Yan Wang, En-Qiang Chen","doi":"10.14218/JCTH.2023.00272","DOIUrl":"10.14218/JCTH.2023.00272","url":null,"abstract":"<p><strong>Background and aims: </strong>Direct evidence on the outcomes of hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients with normal alanine transaminase after long-term antiviral treatment is lacking.</p><p><strong>Methods: </strong>HBeAg-negative patients with normal ALT and positive HBV DNA (≥20 IU/mL) were retrospectively enrolled. The endpoints included virological response (HBV DNA<100 IU/mL), changes in aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 index (FIB-4), and the incidence of liver nodules, cirrhosis, and hepatocellular carcinoma (HCC).</p><p><strong>Results: </strong>This cohort (<i>n</i>=194) was divided into three subgroups, untreated (<i>n</i>=67), treatment-continued (<i>n</i>=87), and treatment-discontinued patients (<i>n</i>=40), with a median follow-up of 54 months. The treatment-continued group achieved 100% (95% CI: 94.7-100) virological response, and significantly reduced APRI and FIB-4 scores (both <i>p</i><0.001). The risk of liver nodules and cirrhosis in that group was reduced by 76% (HR: 0.24, 95% CI: 0.11-0.54, <i>p</i><0.001) and 89% (HR: 0.11, 95% CI: 0.14-0.91, <i>p</i>=0.041) vs. the untreated group and by 77% (HR: 0.23, 95% CI: 0.10-0.49, <i>p</i><0.001) and 95% (HR: 0.05, 95% CI: 0.01-0.44, <i>p</i>=0.006) vs. the treatment-discontinued group. For patients with HBV DNA≥2,000 IU/mL, adherence to treatment lowered the risks of liver cirrhosis by 92% (95% CI: 0.01-0.67) and 93% (95% CI: 0.01-0.53) vs. the untreated and treatment-discontinued patients, respectively. No patient adhering to treatment developed HCC, but one in each of the remaining groups did.</p><p><strong>Conclusions: </strong>Continuous nucleos(t)ide analog (NA) treatment has a satisfactory effectiveness and helps to lower the risk of liver cirrhosis in HBeAg-negative CHB patients with normal alanine transaminase, especially in those with HBV DNA≥2,000 IU/mL.</p>","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"1 1","pages":"1465-1475"},"PeriodicalIF":3.6,"publicationDate":"2023-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10752813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66777826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma (2022 version). 肝内胆管癌病理诊断专家共识(2022 年版)。
IF 3.6 3区 医学
Journal of Clinical and Translational Hepatology Pub Date : 2023-12-28 Epub Date: 2023-07-24 DOI: 10.14218/JCTH.2023.00118
Han Wang, Jun Chen, Xin Zhang, Xia Sheng, Xiao-Yan Chang, Jie Chen, Min-Shan Chen, Hui Dong, Guang-Jie Duan, He-Ping Hu, Zhi-Yong Huang, Wei-Dong Jia, Xiao-Qing Jiang, Dong Kuang, Shan-Shan Li, Zeng-Shan Li, Chang-Li Lu, Shu-Kui Qin, Xue-Shan Qiu, Li-Juan Qu, Chun-Kui Shao, Feng Shen, Guo-Ming Shi, Su-Sheng Shi, Yu-Jun Shi, Hui-Chuan Sun, Xiao-Dong Teng, Bin Wang, Zhan-Bo Wang, Tian-Fu Wen, Jia-Mei Yang, Qiao-Qiao Yang, Sheng-Long Ye, Hong-Fang Yin, Zhen-Gang Yuan, Jing-Ping Yun, Feng-Lin Zang, Hong-Qi Zhang, Li-Hong Zhang, Jing-Min Zhao, Jian Zhou, Wei-Xun Zhou, Jia Fan, Xiao-Ping Chen, Wan Yee Lau, Yuan Ji, Wen-Ming Cong
{"title":"Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma (2022 version).","authors":"Han Wang, Jun Chen, Xin Zhang, Xia Sheng, Xiao-Yan Chang, Jie Chen, Min-Shan Chen, Hui Dong, Guang-Jie Duan, He-Ping Hu, Zhi-Yong Huang, Wei-Dong Jia, Xiao-Qing Jiang, Dong Kuang, Shan-Shan Li, Zeng-Shan Li, Chang-Li Lu, Shu-Kui Qin, Xue-Shan Qiu, Li-Juan Qu, Chun-Kui Shao, Feng Shen, Guo-Ming Shi, Su-Sheng Shi, Yu-Jun Shi, Hui-Chuan Sun, Xiao-Dong Teng, Bin Wang, Zhan-Bo Wang, Tian-Fu Wen, Jia-Mei Yang, Qiao-Qiao Yang, Sheng-Long Ye, Hong-Fang Yin, Zhen-Gang Yuan, Jing-Ping Yun, Feng-Lin Zang, Hong-Qi Zhang, Li-Hong Zhang, Jing-Min Zhao, Jian Zhou, Wei-Xun Zhou, Jia Fan, Xiao-Ping Chen, Wan Yee Lau, Yuan Ji, Wen-Ming Cong","doi":"10.14218/JCTH.2023.00118","DOIUrl":"10.14218/JCTH.2023.00118","url":null,"abstract":"<p><p>Intrahepatic cholangiocarcinoma (iCCA) can originate from the large bile duct group (segment bile ducts and area bile ducts), small bile duct group (septal bile ducts and interlobular bile ducts), and terminal bile duct group (bile ductules and canals of Hering) of the intrahepatic biliary tree, which can be histopathological corresponding to large duct type iCCA, small duct type iCCA and iCCA with ductal plate malformation pattern, and cholangiolocarcinoma, respectively. The challenge in pathological diagnosis of above subtypes of iCCA falls in the distinction of cellular morphologies, tissue structures, growth patterns, invasive behaviors, immunophenotypes, molecular mutations, and surgical prognoses. For these reasons, this expert consensus provides nine recommendations as a reference for standardizing and refining the diagnosis of pathological subtypes of iCCA, mainly based on the 5<sup>th</sup> edition of the World Health Organization Classification of Tumours of the Digestive System.</p>","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"11 7","pages":"1553-1564"},"PeriodicalIF":3.6,"publicationDate":"2023-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10752808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139074256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Differential Mortality Outcomes in Real-world Patients with Lean, Nonobese, and Obese Nonalcoholic Fatty Liver Disease. 现实世界中瘦型、非肥胖型和肥胖型非酒精性脂肪肝患者的不同死亡率结果。
IF 3.6 3区 医学
Journal of Clinical and Translational Hepatology Pub Date : 2023-12-28 Epub Date: 2023-11-27 DOI: 10.14218/JCTH.2023.00016
Vy H Nguyen, Audrey Ha, Nicholas Ajit Rouillard, Richard Hieu Le, Ashley Fong, Surya Gudapati, Jung Eun Park, Mayumi Maeda, Scott Barnett, Ramsey Cheung, Mindie H Nguyen
{"title":"Differential Mortality Outcomes in Real-world Patients with Lean, Nonobese, and Obese Nonalcoholic Fatty Liver Disease.","authors":"Vy H Nguyen, Audrey Ha, Nicholas Ajit Rouillard, Richard Hieu Le, Ashley Fong, Surya Gudapati, Jung Eun Park, Mayumi Maeda, Scott Barnett, Ramsey Cheung, Mindie H Nguyen","doi":"10.14218/JCTH.2023.00016","DOIUrl":"10.14218/JCTH.2023.00016","url":null,"abstract":"<p><strong>Background and aims: </strong>Nonalcoholic fatty liver disease (NAFLD) is commonly associated with obesity but can develop in normal-weight people (lean NAFLD). We compared outcomes in lean, overweight, and obese NAFLD.</p><p><strong>Methods: </strong>This retrospective chart review included patients at Stanford University Medical Center with NAFLD confirmed by imaging between March 1995 and December 2021. Lean, overweight, and obese patients had body mass index of <25.0, >25.0 and <29.9, and ≥30.0 kg/m<sup>2</sup> for non-Asian and >23.0 and ≥27.5 for overweight and obese Asian patients.</p><p><strong>Results: </strong>A total of 9061 lean (10.2%), overweight (31.7%), and obese (58.1%) patients were included. Lean patients were 5 years older than obese patients (53±17.4 vs. 48.7±15.1 years), more were female (59.6% vs. 55.2%), white (49.1% vs. 46.5%), had NASH (29.2% vs. 22.5%), cirrhosis (25.3% vs.19.2%), or nonliver cancer (25.3% vs. 18.3%). Fewer had diabetes (21.7% vs. 35.8%) or metabolic comorbidities (all <i>p</i><0.0001). Lean NAFLD patients had liver-related mortality similar to other groups but higher overall (<i>p</i>=0.01) and nonliver-related (<i>p</i>=0.02) mortality. After multivariable model adjustment for covariates, differences between lean and obese NAFLD in liver-related, nonliver-related, and overall mortality (adjusted hazard ratios of 1.34, 1.00, and 1.32; <i>p</i>=0.66, 0.99, and 0.20, respectively) were not significant.</p><p><strong>Conclusions: </strong>Lean NAFLD had fewer metabolic comorbidities but similar adverse or worse outcomes, suggesting that it is not benign. Healthcare providers should provide the same level of care and intervention as for overweight and obese NAFLD.</p>","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"11 7","pages":"1448-1454"},"PeriodicalIF":3.6,"publicationDate":"2023-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10752812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139074255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Focal Nodular Hyperplasia: A Comprehensive Review with a Particular Focus on Pathogenesis and Complications 局灶性结节性增生:全面综述,特别关注发病机制和并发症
IF 3.6 3区 医学
Journal of Clinical and Translational Hepatology Pub Date : 2023-12-21 DOI: 10.14218/jcth.2023.00265
Jaimy Villavicencio Kim, George Y. Wu
{"title":"Focal Nodular Hyperplasia: A Comprehensive Review with a Particular Focus on Pathogenesis and Complications","authors":"Jaimy Villavicencio Kim, George Y. Wu","doi":"10.14218/jcth.2023.00265","DOIUrl":"https://doi.org/10.14218/jcth.2023.00265","url":null,"abstract":"","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"26 23","pages":""},"PeriodicalIF":3.6,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138950421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信